Stock Events

Stock Events

Can-Fite Biopharma 

$3.6
13
-$0.28-7.24% Today

Statistics

Day High
3.71
Day Low
3.52
52W High
23
52W Low
2.9
Volume
880,826
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

26MarExpected
Q1 2023
Q1 2024
Q2 2024
Q3 2024
Q1 2025
Q2 2025
Q4 2025
-0.19
-0.13
-0.06
0
Expected EPS
0
Actual EPS
N/A

Financials

-1,169.14%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
1.35MRevenue
-15.76MNet Income

Analyst Ratings

4Average Price Target
The highest estimate is 4.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CANF. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap163.4B
Gilead Sciences is a biopharmaceutical company that competes in the development of drugs in areas such as inflammation and oncology, similar to Can-Fite's focus areas.
Abbvie
ABBV
Mkt Cap365.43B
AbbVie operates in the same therapeutic areas as Can-Fite, including inflammation and cancer, making it a direct competitor in drug development.
AMGEN
AMGN
Mkt Cap178B
Amgen focuses on innovative therapeutics in areas like oncology and inflammation, directly competing with Can-Fite's product pipeline.
Bristol-Myers Squibb
BMY
Mkt Cap118.87B
Bristol Myers Squibb is involved in discovering, developing, and delivering innovative medicines in cancer and immune-inflammatory diseases, overlapping with Can-Fite's interests.
Pfizer
PFE
Mkt Cap149.77B
Pfizer engages in the discovery, development, and manufacture of healthcare products including medicines and vaccines for immunology and oncology, competing with Can-Fite.
Merck
MRK
Mkt Cap277.02B
Merck operates in the pharmaceutical industry focusing on cancer and inflammatory diseases, making it a competitor to Can-Fite in these therapeutic areas.
Novartis
NVS
Mkt Cap279.67B
Novartis focuses on a broad range of healthcare areas including advanced therapy platforms in oncology and rheumatology, competing with Can-Fite's research and development.
Roche
RHHBY
Mkt Cap328.49B
Roche develops and markets medications and diagnostic instruments in oncology, immunology, and infectious diseases, areas that Can-Fite is also targeting.
Astrazeneca
AZN
Mkt Cap286.4B
AstraZeneca is a global, science-led biopharmaceutical business that operates in the main therapy areas of cancer and autoimmune diseases, directly competing with Can-Fite.
Johnson & Johnson
JNJ
Mkt Cap546.9B
Johnson & Johnson, through its pharmaceutical segment, develops treatments for a wide range of diseases, including those in Can-Fite's focus areas, making it a competitor.

About

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.
Show more...
CEO
Dr. Pnina Fishman Ph.D.
Employees
5
Country
Israel
ISIN
US13471N4097

Listings

STU
DE
CF5.STU
XASE
US
CANF
TA
IL
CANF.TA
BOATS
BOATS
CANF.BOATS

0 Comments

Share your thoughts

FAQ

What is Can-Fite Biopharma stock price today?▼
The current price of CANF is $3.6 USD — it has decreased by -7.24% in the past 24 hours. Watch Can-Fite Biopharma stock price performance more closely on the chart.
What is Can-Fite Biopharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Can-Fite Biopharma stocks are traded under the ticker CANF.
Is Can-Fite Biopharma stock price growing?▼
CANF stock has risen by +20.68% compared to the previous week, the month change is a +16.34% rise, over the last year Can-Fite Biopharma has showed a -83.67% decrease.
When is the next Can-Fite Biopharma earnings date?▼
Can-Fite Biopharma is going to release the next earnings report on August 27, 2026.
What is Can-Fite Biopharma revenue for the last year?▼
Can-Fite Biopharma revenue for the last year amounts to 1.35M USD.
What is Can-Fite Biopharma net income for the last year?▼
CANF net income for the last year is -15.76M USD.
How many employees does Can-Fite Biopharma have?▼
As of May 06, 2026, the company has 5 employees.
In which sector is Can-Fite Biopharma located?▼
Can-Fite Biopharma operates in the Health & Wellness sector.
When did Can-Fite Biopharma complete a stock split?▼
The last stock split for Can-Fite Biopharma was on January 05, 2026 with a ratio of 1:20.
Where is Can-Fite Biopharma headquartered?▼
Can-Fite Biopharma is headquartered in Ramat Gan, Israel.